3/5
07:56 am
tak
Takeda Pharmaceutical (TAK) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Takeda Pharmaceutical (TAK) was upgraded by Zacks Research from "strong sell" to "hold".
3/4
04:31 pm
tak
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/4
12:51 pm
tak
Takeda plans to lay off 400 employees in US - report [Seeking Alpha]
Low
Report
Takeda plans to lay off 400 employees in US - report [Seeking Alpha]
3/2
02:00 am
tak
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Low
Report
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
2/19
12:00 pm
tak
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Low
Report
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
2/16
02:23 am
tak
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After A Strong Run In Recent Months [Yahoo! Finance]
Low
Report
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After A Strong Run In Recent Months [Yahoo! Finance]
2/10
03:15 am
tak
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Low
Report
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
2/2
03:24 am
tak
Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]
Low
Report
Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]
2/2
12:26 am
tak
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]
1/31
09:57 am
tak
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]
Low
Report
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]
1/31
01:33 am
tak
Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at
Wall Street
Low
Report
Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at
Wall Street
1/30
02:16 pm
tak
Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]
Low
Report
Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]
1/29
01:37 am
tak
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Medium
Report
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
1/22
07:45 am
tak
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
Low
Report
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
1/21
07:04 pm
tak
Assessing Takeda Pharmaceutical (TSE:4502) After Recent Pipeline Progress And Share Price Moves [Yahoo! Finance]
Low
Report
Assessing Takeda Pharmaceutical (TSE:4502) After Recent Pipeline Progress And Share Price Moves [Yahoo! Finance]
1/13
08:42 am
tak
Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
1/9
05:18 pm
tak
Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]
1/5
07:00 am
tak
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Low
Report
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
12/30
11:04 am
tak
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
Low
Report
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
12/29
09:47 am
tak
Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]
Low
Report
Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]
12/24
09:31 pm
tak
????????????????????:???????????????????????????????????????????????????2033????61?3000????????????? [CNET News]
Low
Report
????????????????????:???????????????????????????????????????????????????2033????61?3000????????????? [CNET News]
12/18
04:24 am
tak
Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies [Yahoo! Finance]
12/18
03:00 am
tak
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Medium
Report
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
12/6
09:30 am
tak
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Low
Report
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera